This study is in progress, not accepting new patients
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
Disease, Hodgkin Antigens, CD30 Antibody-Drug Conjugate Antibodies, Monoclonal Drug Therapy Hematologic Diseases Immunotherapy Lymphoma Monomethylauristatin E Hodgkin Disease brentuximab vedotin
Lead Scientist at UCSF
- Weiyun Ai
Professor, Medicine. Authored (or co-authored) 46 research publications.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Seattle Genetics, Inc.
- Phase 3
- Study Type
- Last Updated